Neurocrine Biosciences, Inc. financials
Key figures from Neurocrine Biosciences, Inc.'s filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $959M | $688M | +39.5% |
| Net income | $144M | $108M | +34.3% |
| Free cash flow | $129M | $90M | +43.7% |
| Gross margin | — | 98.4% | — |
| Operating margin | 15.8% | 21.2% | -5.4 pts |
| Net margin | 15.1% | 15.6% | -0.6 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $2.9B | $479M | 16.7% | $749M | $4.67 |
| FY Dec 2024 | $2.4B | $341M | 14.5% | $557M | $3.29 |
| FY Dec 2023 | $1.9B | $250M | 13.2% | $362M | $2.47 |
| FY Dec 2022 | $1.5B | $155M | 10.4% | $323M | $1.56 |
| FY Dec 2021 | $1.1B | $90M | 7.9% | $233M | $0.92 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.